58 studies found for:    ovarian,cancer,PARP
Show Display Options
Rank Status Study
1 Active, not recruiting AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Conditions: Breast Cancer;   Ovarian Cancer
Intervention: Drug: AZ2281 + Carboplatin
2 Recruiting POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention: Drug: BMN 673
3 Recruiting BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Condition: Ovarian Cancer
Intervention: Drug: BMN 673 (talazoparib)
4 Withdrawn Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Olaparib
5 Active, not recruiting
Has Results
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Condition: Ovarian Neoplasm
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
6 Completed Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Conditions: brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer;   Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338);   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
7 Completed A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: BSI-201
8 Completed A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Drug: BSI-201
9 Active, not recruiting Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Conditions: Cervical Cancer;   Ovarian Cancer;   Breast Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Endometrial Cancer
Interventions: Drug: Carboplatin;   Drug: Olaparib
10 Active, not recruiting ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin s Lymphoma
Conditions: Ovarian;   Primary Peritoneal;   Serous Carcinoma;   Triple-Negative Breast;   Fallopian Tube
Intervention: Drug: ABT-888 + Cyclophospharmide
11 Active, not recruiting A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
12 Active, not recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
13 Recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
14 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Veliparib
15 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Drug: Veliparib
16 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Floxuridine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
17 Recruiting Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Conditions: Adult Solid Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
18 Recruiting A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
Condition: Ovarian Cancer
Intervention: Drug: Niraparib
19 Active, not recruiting Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Veliparib
20 Active, not recruiting
Has Results
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Conditions: Ovarian Carcinoma;   Breast Cancer
Intervention: Drug: AZD2281

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years